We show that the overexpression of HER2/neu and Ki-67 correlates positively with higher tumor grade, advanced stage and may serve as reliable prognostic biomarkers thus guiding therapeutic decision making in management of urothelial carcinoma. The gene discussed is ERBB2; the disease is urothelial carcinoma.